Specialty Pharmacy

Wilate, a von Willebrand factor replacement therapy, was approved for use in patients with hemophilia A for routine prophylaxis and on demand treatment and control of bleeding episodes.

Certain cancer agents may have drug-food or drug-drug interactions that alter exposure to the medication, resulting in a need for individualized dosing.

The National Association of Specialty Pharmacy's annual meeting is one of the industry’s only conferences where all stakeholders can fully participate.

Top news of the day from across the health care landscape.

Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.

The new drug application for PF708 was submitted under the 505(b)(2) regulatory pathway with teriparatide injection as the reference drug.

The keynote, Priming Pharmacists for Making an Impact in Oncology Value-Based Care, sets the stage for the entire conference and highlights how pharmacists are critical to the multidisciplinary team in providing value in patient-centered oncology care.

Ron Lanton III, Esq., discusses the Prescription Drug Price Relief Act of 2019 at the National Association of Specialty Pharmacists Annual Meeting at Washington, DC.

Top news of the day from across the health care landscape.

A new study by Prime Therapeutics LLC has shown a sharp increase in the number of drug "super spenders," defined by the researchers as members with pharmacy and medical drug therapy claims of $250,000 or more annually.

Ixekizumab showed superiority versus guselkumab in the treatment of moderate to severe plaque psoriasis.

Subcutaneous immunoglobin has increased treatment options for patients with several conditions, such as primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy.

The PARP inhibitor received a Breakthrough Therapy Designation for metastatic castration-resistant prostate cancer based on data released from the GALAHAD study.

Top news of the day from across the health care landscape.

The FDA has awarded a cooperative agreement grant to the National Association of Boards of Pharmacy to develop a 3-year pilot project for a data-sharing system to improve oversight of compounding pharmacies.

Top news of the day from across the health care landscape.

Two cell mutations have been linked to acute myeloid leukemia, but the reason for their cooperation has been unknown.

The funding is awarded to health departments representing 57 geographic areas to expand treatment and prevention efforts for HIV/AIDS.

The black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades.

Study offers a new perspective on the molecular events that may lead some individuals to develop multiple sclerosis.

Top news of the day from across the health care landscape.

The PREVENT trial revealed that secukinumab demonstrated both efficacy and a favorable safety profile for patients with non-radiographic axial spondyloarthritis (nr-axSpA).

The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.

Top news of the day from across the health care landscape.

Niraparib (Zejula) found to prolong time without symptoms or toxicity in patients with ovarian cancer.

The FDA’s accelerated approval program has been criticized recently for pushing drugs into the market before they undergo randomized phase 3 clinical trials.

Top news of the day from across the health care landscape.

Fulvestrant injection treats certain types of breast cancer in post-menopausal women who were not previously treated with endocrine therapy and as a combination for advanced or metastatic breast cancer.

Ivosidenib improved progression-free survival with a promising trend toward improved overall survival in patients with IDH1-mutated cholangiocarcinoma.

Apalutamide (Erleada) showed an overall survival benefit in patients with non-metastatic castration-resistant prostate cancer.